头颈鳞癌在线自适应放疗的剂量学优势:前瞻性登记研究结果
该回顾性分析纳入69例接受根治性放疗的头颈鳞癌患者,至少一次使用Varian Ethos系统在线自适应放疗(oART)。自适应计划较原计划显著改善所有PTV的V100覆盖(95.83% vs 89.58%,P < .001)及PTV70的D95%和D99%,并减小接受超过处方剂量103%的体积(-19.04 cc,P = .007),但唾液腺剂量无显著差异。
要点
- 自适应计划所有PTV的V100覆盖为95.83%,高于原计划的89.58%(P < .001)。
- PTV70的D95%和D99%在自适应计划中分别为99.63%和95.64%,均显著高于原计划。
- 自适应计划接受超过处方剂量103%的体积较原计划减少19.04 cc(P = .007)。
核心结论
- 在线自适应放疗与覆盖率和剂量均匀性显著改善相关,但未带来更优的OAR保护。
- 需要进一步研究以优化选择适合oART的患者并确定这些剂量学优势的临床获益。
研究设计与样本
- 回顾性分析纳入69例接受根治性治疗的头颈鳞癌患者,于2021年9月至2024年3月在单一三级医疗机构使用Varian Ethos系统行oART至少一次。
- 剂量学结局采用t检验比较,分析PTV覆盖和平均剂量及OAR剂量,并记录每次治疗的分次交付时间。
主要发现
- 队列主要包含口咽癌(n = 46,66.7%)和喉/下咽癌(n = 15,21.7%)患者。
- 自适应计划所有PTV的V100覆盖为95.83% vs 原计划89.58%(P < .001),PTV70的D95%为99.63% vs 95.69%(P < .001),D99%为95.64% vs 87.82%(P < .001)。
- 自适应计划接受超过处方剂量103%的体积较原计划减少19.04 cc(P = .007)。
- 任何唾液腺的剂量分布无显著差异,其他OAR差异临床上不显著。
- 平均总自适应工作流程时间为17分钟(SD,1.9分钟),平均总在室时间为36分钟(SD,2.3分钟)。
临床怎么用
- 在线自适应放疗可改善头颈鳞癌靶区覆盖和剂量均匀性,但未显示更优的OAR保护。
- 患者选择和临床获益需进一步研究确定。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Data are limited on the feasibility and dosimetric advantages of cone beam computed tomography-based online adaptive radiation therapy (oART) in head and neck squamous cell carcinoma. In this retrospective analysis, we assessed the dosimetric outcomes in patients receiving definitive radiation therapy and treated with oART at least once during their treatment course. METHODS AND MATERIALS: We retrospectively analyzed 69 patients with head and neck squamous cell carcinoma who received definitive-intent treatment and oART using the Varian Ethos system at a single tertiary care institution between September 2021 and March 2024. Dosimetric outcomes were compared using a t test. The coverage and mean doses of the planning target volumes (PTVs) and the dose to organs-at-risk (OARs) was analyzed. Conformality and heterogeneity were compared with the conformality index, maximum hotspot, and the absolute volume receiving 103%, 105%, and 107% of the maximum prescribed dose. Treatment delivery time was also recorded for each fraction. RESULTS: The cohort was primarily comprised of patients diagnosed with oropharynx (n = 46, 66.7%) and larynx/hypopharynx (n = 15, 21.7%) cancers. Adapted plans had significantly improved coverage when using the V100 as the coverage metric (95.83% vs 89.58%, P < .001) for all PTVs and improved D95% (99.63% vs 95.69%, P < .001) and D99% (95.64% vs 87.82%, P < .001) of the PTV70. The adapted plans also had a substantially smaller volume receiving above 103% of the prescription (-19.04 cc, P = .007). There was no significant difference in the dose distributions of any salivary glands, and the differences in other OARs were clinically insignificant. The mean total adaptive workflow time was 17 (SD, 1.9) minutes, and the mean total in-room time was 36 minutes (SD, 2.3 minutes). CONCLUSIONS: Online ART is associated with significantly improved coverage and dose homogeneity but not superior OAR sparing. Additional research is needed to optimally select patients for oART and determine the clinical benefits of these dosimetric advantages.
引用
- Shi JJ, Meduri K, Liao CY, et al. Dosimetric Advantages of Online Adaptive Radiation Therapy for Head and Neck Squamous Cell Carcinoma: Results From a Prospective Registry Study. Int J Radiat Oncol Biol Phys. 2025. PMID: 40164349. doi:10.1016/j.ijrobp.2025.03.050
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。